Fundraising Fox

Roche Venture FundFull Portfolio

26 tracked investments · listed companies and verified rows first

Enliven Therapeuticsenliventherapeutics.cominNASDAQ: ELVN
Entrada Therapeutics, Inc.entradatx.cominNASDAQ: TRDA

Entrada Therapeutics develops intracellular therapeutics using its EEV Platform to target previously inaccessible disease-causing targets within cells, with a pipeline spanning retinal, neuromuscular, and metabolic diseases including Duchenne muscular dystrophy.

BiotechHealthtechMedical DevicesBoston, US

Natarajan Sethuraman(Executive Officer)Peter Kim(Director)Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)Dipal Doshi(Executive Officer, Director)inJohn F. Crowley(Director)

Freenomefreenome.cominNASDAQ: FRNMOct 2015

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)Stuart Lawson(Director)Charles Roberts(Director)Gabriel Otte(Director)

DiogenX’s websitediogenx.comin✓ verified

DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.

BiotechDeep TechDigital HealthHealthtechMarseille, FR

Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)Jean-Pascal Tranié(Co-Founder)

Splice Biosplice.bioin𝕏✓ verified

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)

Macrolide PharmaceuticalsMar 2018SEC filingmedium confidence

BiotechWatertown, US

Markus Goebel(Director)Christopher Viehbacher(Director)Joseph Zakrzewski(Director)Henry Skinner(Director)Mary Szela(Director)Vikas Goyal(Director)

Board seatAnja Harmeier· per SEC Form D · $20M raise · filed Mar 2018

Aligos Therapeuticsaligos.comin𝕏

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.

BiotechHealthtechSouth San Francisco, US

Hardean Achneck(Executive Officer)Carole Neuchterlein(Director)Peter Moldt(Director)Sushmita Chanda(Executive Vice President - Preclinical Development)Kathleen Glaub(Director)Brian Dowd(Executive Vice President - Controller)

Bonum Therapeuticsbonumtx.comin

Bonum Therapeutics is an early-stage biotechnology company.

BiotechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)Neela Patel(Executive Officer)Diane Hollenbaugh(Executive Officer)

BoardSamuel Bjork(Director)Monique Schiersing(Director)John McKearn(Director)

Cour Pharmacourpharma.comin𝕏

COUR develops targeted therapies for autoimmune diseases using an antigen-specific platform technology designed to restore immune tolerance while preserving normal immune function.

BiotechHealthtechMedical Devices

Entheraentherapharmaceuticals.comin

Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.

BiotechHealthtechMilan, IT

Epi Biologicsepibiologics.comin

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Jason Coloma(Director)Ann Lee-Karlon(Executive Officer, Director)Samuel Bjork(Director)Alexandra Cantley(Director)Mitchell Mutz(Executive Officer, Director)Seiji Miyahara(Director)

Forcefieldtxforcefieldtx.com

Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).

BiotechHealthtechMedical Devices

John

GlycoEraglycoera.comin𝕏

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)

Kumquat BiosciencesinFeb 2021

BiotechSan Diego, US

Yi Liu(Executive Officer, Director)Lynn Yang(Director)

BoardCarl Gordon(Director)

MergeTheramergetherapeutics.com
Mironidmironid.comin𝕏

Mironid develops drug therapies targeting cAMP degrading phosphodiesterase enzymes for autosomal dominant polycystic kidney disease and other rare kidney diseases with significant unmet medical needs.

BiotechHealthtechMedical Devices

Adele Rowley(Chief Scientific Officer)

Mission Therapeuticsmissiontherapeutics.comin𝕏

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

NMD Pharmanmdpharma.comin𝕏

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.

BiotechDeep TechHealthtechMedical DevicesAarhus, DK

Noema Pharmanoemapharma.comin

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)

Photo of Tempest Therapeuticstempesttx.com

BiotechBrisbane, US

Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)

Receptive Bioreceptivebio.com
River3Renalpharmaceutical-technology.comin𝕏

Pharmaceutical-technology.com is a B2B media and news website covering pharma, biotech, medical technology, and health tech, part of GlobalData's network of proprietary industry sites.

HealthtechMedia & EntertainmentLondon, GB

Sarepta Therapeuticssarepta.comin𝕏

Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.

BiotechHealthtechCambridge, US

WILLIAM CIAMBRONE(Executive Officer)HANS WIGZELL(Director)CLAUDE NICAISE(Director)DOUGLAS S. INGRAM(Executive Officer, Director)DAVID TYRONNE HOWTON(Executive Officer)MARY ANN GRAY(Director)

Vivet Therapeuticsvivet-therapeutics.comin𝕏

Vivet Therapeutics is a company focused on gene and cell therapy development, presenting research at major scientific conferences.

BiotechParis, FR

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.